Curis (CRIS +4.8%) grabs some attention from analysts after landing FDA approval for Erivedge....

|By:, SA News Editor

Curis (CRIS +4.8%) grabs some attention from analysts after landing FDA approval for Erivedge. Oppenheimer raised its rating to Outperform with a new price target of $7.50, while Summer Street reiterated a Buy rating with a $7 PT. Shares have sputtered since the news broke on a bit of buy-the-rumor, sell-the-news trading.